Marvel Biosciences Corp. operates as a pre-clinical stage pharmaceutical development biotechnology company. It engages in the discovery and development of synthetic derivative compounds of known drugs that inhibit the A2a adenosine receptor. The company offers Nourianz (Istradefylline, KW-6002), an adenosine A2A receptor antagonist. It targets neurological diseases, such as Alzheimer's disease, depression and anxiety, and addictions; non-neurological conditions of cancer; and non-alcoholic steatohepatitis. Marvel Biosciences Corp. is headquartered in Calgary, Canada.